ÂÜÀòÂÒÂ×

Gregg Lapointe is a co-founder of Cerium Pharmaceuticals, Inc. His background includes extensive experience in the areas of global strategic planning, business development, corporate finance, licensing and acquisitions. He previously served in varying roles for Sigma-Tau Pharmaceuticals, Inc., a private biopharmaceutical company, starting in 2001, including Chief Financial Officer from 2001 to 2002, Chief Operating Officer from 2003 to 2007, and Chief Executive Officer from 2008 to 2012. Mr. Lapointe led the effort to transform Sigma-Tau Pharmaceuticals from a small specialty dialysis company into a global leader in the development and commercialization of medicines for Rare Diseases.

Mr. Lapointe has extensive experience serving on the Boards of Directors of several public biopharmaceutical companies. He currently serves on the Boards of Rigel Pharmaceuticals, Inc., Soligenix, Inc., and Astria Therapeutics, Inc., and has previously served on the Boards of SciClone Pharmaceuticals, Inc., Raptor Pharmaceuticals, Inc., Immunocellular Therapeutics, Ltd., Questcor Pharmaceuticals, Inc., and Cytori Therapeutics.

He holds a Bachelor of Commerce degree from Concordia University (Montreal), a Graduate Diploma in Public Accountancy from McGill University (Montreal), and an MBA from Duke University. Mr. Lapointe is a Certified Public Accountant, licensed in the State of Illinois.